AU2011201888A1 - Water-soluble compositions of bioactive lipophilic compounds - Google Patents
Water-soluble compositions of bioactive lipophilic compounds Download PDFInfo
- Publication number
- AU2011201888A1 AU2011201888A1 AU2011201888A AU2011201888A AU2011201888A1 AU 2011201888 A1 AU2011201888 A1 AU 2011201888A1 AU 2011201888 A AU2011201888 A AU 2011201888A AU 2011201888 A AU2011201888 A AU 2011201888A AU 2011201888 A1 AU2011201888 A1 AU 2011201888A1
- Authority
- AU
- Australia
- Prior art keywords
- water
- soluble
- coenzyme
- pts
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 201
- 150000002634 lipophilic molecules Chemical class 0.000 title description 40
- 230000000975 bioactive effect Effects 0.000 title description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 126
- 239000002904 solvent Substances 0.000 claims description 99
- 150000001875 compounds Chemical class 0.000 claims description 54
- 229940116351 sebacate Drugs 0.000 claims description 32
- 239000003921 oil Substances 0.000 claims description 16
- 235000019198 oils Nutrition 0.000 claims description 16
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 claims description 14
- 229950005143 sitosterol Drugs 0.000 claims description 14
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 107
- 235000017471 coenzyme Q10 Nutrition 0.000 description 65
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 58
- 239000000243 solution Substances 0.000 description 53
- 238000000034 method Methods 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 47
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 41
- 238000009472 formulation Methods 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 28
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 28
- 239000011709 vitamin E Substances 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 235000019165 vitamin E Nutrition 0.000 description 27
- 229940046009 vitamin E Drugs 0.000 description 27
- 229930003427 Vitamin E Natural products 0.000 description 26
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 26
- 239000003960 organic solvent Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 239000007864 aqueous solution Substances 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 19
- 229960003942 amphotericin b Drugs 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000011732 tocopherol Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 239000005515 coenzyme Substances 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 230000007928 solubilization Effects 0.000 description 14
- 238000005063 solubilization Methods 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- 229930003802 tocotrienol Natural products 0.000 description 14
- 239000011731 tocotrienol Substances 0.000 description 14
- 235000019148 tocotrienols Nutrition 0.000 description 14
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- -1 Vitamin E) Natural products 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 229940110767 coenzyme Q10 Drugs 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 229960000988 nystatin Drugs 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 229940068778 tocotrienols Drugs 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- 206010021143 Hypoxia Diseases 0.000 description 11
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 11
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 229960001295 tocopherol Drugs 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 239000012736 aqueous medium Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 229930182558 Sterol Natural products 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000007954 hypoxia Effects 0.000 description 9
- 239000003120 macrolide antibiotic agent Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 9
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 9
- 150000003432 sterols Chemical class 0.000 description 9
- 235000003702 sterols Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 229930003799 tocopherol Natural products 0.000 description 9
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 9
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 9
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 8
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 8
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 8
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 8
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- 235000015500 sitosterol Nutrition 0.000 description 8
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 8
- 229940040064 ubiquinol Drugs 0.000 description 8
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229960000583 acetic acid Drugs 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 7
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 230000002438 mitochondrial effect Effects 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000002459 polyene antibiotic agent Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 101150039027 ampH gene Proteins 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 229960001265 ciclosporin Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 229930182912 cyclosporin Natural products 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000003104 tissue culture media Substances 0.000 description 5
- 230000000451 tissue damage Effects 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 4
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 4
- 241000221204 Cryptococcus neoformans Species 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 4
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000013793 astaxanthin Nutrition 0.000 description 4
- 239000001168 astaxanthin Substances 0.000 description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 4
- 229940022405 astaxanthin Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229960004348 candicidin Drugs 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- WMPOZLHMGVKUEJ-UHFFFAOYSA-N decanedioyl dichloride Chemical compound ClC(=O)CCCCCCCCC(Cl)=O WMPOZLHMGVKUEJ-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 229920001515 polyalkylene glycol Polymers 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 150000003669 ubiquinones Chemical class 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- TVLSKGDBUQMDPR-UHFFFAOYSA-N 2,3-Dimethoxy-5-methyl-6-(3-methyl-2-buten-1-yl)-1,4-benzenediol Chemical class COC1=C(O)C(C)=C(CC=C(C)C)C(O)=C1OC TVLSKGDBUQMDPR-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
- 201000007336 Cryptococcosis Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
- 235000000431 campesterol Nutrition 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 229920000447 polyanionic polymer Polymers 0.000 description 3
- 150000004291 polyenes Chemical class 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 229920000137 polyphosphoric acid Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000001608 teratocarcinoma Diseases 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 229940044613 1-propanol Drugs 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010549 co-Evaporation Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000002433 hydrophilic molecules Chemical group 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000006540 mitochondrial respiration Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229960005335 propanol Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- LCJINPXTMHVZGV-UHFFFAOYSA-N 2,3,5-triphenyl-1h-tetrazol-4-ium;chloride Chemical compound [Cl-].[NH2+]1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 LCJINPXTMHVZGV-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CNXXEPWXNDFGIG-UHFFFAOYSA-N dodecanedioyl dichloride Chemical class ClC(=O)CCCCCCCCCCC(Cl)=O CNXXEPWXNDFGIG-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 150000003612 tocotrienol derivatives Chemical class 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant(s): NATIONAL RESEARCH COUNCIL OF CANADA Invention Title: WATER-SOLUBLE COMPOSITIONS OF BIOACTIVE LIPOPHILIC COMPOUNDS The following statement is a full description of this invention, including the best method for performing it known to me/us: WATER-SOLUBLE COMPOSITIONS OF BIOACTIVE LIPOPHILIC COMPOUNDS FIELD OF THE INVENTION 5 The present invention relates to water-soluble compositions of bloactive lipophilic compounds, to compounds useful for the preparation of such compositions, to methods of preparing such compounds and compositions, and to the use of such compositions as therapeutics and cosmetics. 10 BACKGROUND OF THE INVENTION Many bioactive compounds are highly lipophilic (hydrophobic), meaning that they are soluble in lipids (oils) and some organic solvents, while being 15 substantially insoluble or only sparsely soluble in water. The lack of solubility of a bioactive compound in aqueous media is an important factor limiting its therapeutic applications, making difficult an efficient administration of the compound to a patient. When administered in the form of an oil solution or some kind of water and/or oil suspension or emulsion, lipophilic compounds usually 20 show a poor bioavailability, meaning a low concentration and a long build-up time of the compound in the systemic circulation. This lack of bioavailability is usually independent of the administration route (topical, oral, or parenteral). Various approaches to overcoming this limitation are known in the prior 25 art. One known approach consists of dissolving a lipophilic compound in a water miscible organic solvent, such as ethanol or propylene glycol. When such a solution is admixed with blood or gastrointestinal fluids, however, the lipophilic compound usually precipitates as a solid or liquid emulsion, with a resulting low bioavailability. Furthermore, for many lipophilic compounds no organic, water 30 miscible solvents exist. Another approach consists of incorporating lipophilic compounds into various compositions, frequently inhomogeneous, multiphase 1A emulsions, containing oils and solvents in combination with surfactants. These compositions may improve the bioavailability of the compound without significantly increasing its solubility in aqueous media, but are normally suitable only for a particular administration form, usually for topical applications. Such 5 compositions, which may also Induce a protective immune response in mammals, are of little value for therapeutic uses where administration of the compound by ingestion or injection is necessary and where an aqueous solution or a water-soluble solid composition is frequently the only acceptable administration form. 10 Several approaches to preparing homogenous aqueous solutions of lipophilic bioactive compounds are also known in the prior art. One method consists of preparing a derivative or an analog of a lipophilic compound having a better solubility in water than the original compound. In the simplest case, this is derivative may be a water-soluble salt of the compound, which salt usually retains the original biological activity, but this approach is applicable only to compounds having acidic or basic properties. If more substantial modifications are introduced into the original compound to improve its solubility, a decrease or even a complete loss of the original bioactivity of the compound is frequently 20 observed. Another method of solubilization consists of preparing a water-soluble derivative capable of* liberating the original bioactive compound under physiological conditions. Such derivatives, also known as pro-drugs, usually 25 improve bioavailability of.the compound and may also ensure a targeted delivery of the compound or its sustained release over a period of time. However, this approach usually relies on the presence of certain functional groups in the original compound, so it Is not universally applicable. In addition, synthetic methods of Improving solubility of a compound by chemical modifications are 30 relatively complicated and expensive. 2 Still another approach to solubilization of bloactive lipophilic compounds relies on formation of water-soluble complexes. An example are complexes with amphipathic compounds containing moieties of two opposing solubility tendencies (lipophilic and hydrophilic). Such compounds are often soluble both 5 in organic solvents and in water, so that the solubilization is usually achieved by dissolving a bioactive lipophilic compound and an amphipathic compound in a suitable water-miscible organic solvent and diluting the solution with water. In some cases the organic solvent is partially or entirely removed from the original or water-diluted solution by evaporation or lyophilization and the concentrate 10 reconstituted with a suitable aqueous medium, without precipitation of the water insoluble lipophilic compound. When the auxiliary organic solvent cannot be completely removed from the composition, this solvent must be pharmaceutically acceptable, which limits the choice of applicable solvents. 15 Bioactive lipophilic compounds in need of solubilization belong to various therapeutic categories, such as vitamins (e.g., Vitamin E), antibiotics, in particular macrolide polyene antibiotics (amphotericin-B, nystatin, candicidin), free radicals scavengers (e.g., tocopherols, ubiquinones), immunosuppressants (e.g., cyclosporine), etc. Various approaches to achieve the solubility and 20 improve the bioavailability of these and other lipophilic compounds are known in the prior art, including formation of water-soluble complexes. US patent No. 5,686,110 discloses water-soluble complexes of water insoluble compounds, including amphotericin-B and cyclosporine, with a 25 polyalkylene oxide polymers end-capped with an alkyl or olefinic group, which polymers are soluble both in water and In organic solvents. The water-soluble complexes, which are formed only in the presence of an auxiliary organic solvent, are lyophilized and reconstituted with a buffer solution. The reconstituted aqueous solutions show only a limited stability, depending mostly on the pH of 30 the solution. Furthermore, the use of methoxypolyethylene glycol polymers of relatively high molecularweight (2,000 to 5,000) as preferred solubilizing agents 3 Increases the amount by weight of polymer necessary for solubilization of the, bioactive compound. US 5,798,333 discloses a homogenous, water-soluble composition 5 (concentrate) of cyclosporine, which can be diluted with an aqueous solution without precipitation of cyclosporine. The concentrate comprises cyclosporine and tocophersolan (polyoxyethanyl-a-tocopheryl succinate, TPGS) dissolved in a hydrophilic organic solvent, such as propylene glycol. Solvent-free compositions are not disclosed, as they would likely be unstable or inhomogeneous. 10 WO 96/17626 discloses water-soluble compositions of ubiquinones comprising polyoxyethanyl-cholesteryl sebacate (PCS) as a solubilizing agent. A ubiquinone, in particular Coenzyme Q1o, is solubilized by dissolving both Coenzyme Q1o and PCS in tetrahydrofuran at an approximate molar ratio of 1:3 5 and diluting this solution with water. The solution Is then evaporated to dryness under reduced pressure and reconstituted with a suitable buffer solution. Coenzyme Q1o (CoQ 1 o) is a natural compound whose therapeutic potential has been recently recognized for a number of disorders, including 20 congestive heart failure, muscular distrophy, periodontal disease, correction of drug-induced deficiencies, and immune restoration (AIDS, allergies), to name a few. Coenzyme Q 10 is also of great interest to cosmetic industry, since it can be included into cosmetic preparations as agent slowing down natural skin ageing processes. The biological activity of Coenzyme Q 10 is believed to be linked to its 25 ability to act as an antioxidant and free radical scavenger protecting integrity of cell membranes and to offset the inability of diseased cells to manufacture sufficient energy for cellular repair, by stimulating mitochondrial respiration and production of ATP. For effectiveness in both clinical and cosmetic applications, preparations of Coenzyme Q 1 0 with high bioavailability and solubility in aqueous 30 media are usually required. 4 Even though various methods of improving solubility of lipophilic compounds, such as Coenzyme Q1o, in aqueous media are known In the prior art, they are not equal in terms of simplicity, scope of applicability, stability of the prepared formulations, etc. The present invention provides a new method of 5 solubilization of lipophilic compounds, which is free of many prior art drawbacks and limitations. SUMMARY OF THE INVENTION 10 According to one aspect, the present invention provides a water-soluble composition comprising a lipophilic compound and a solubilizing agent of the general formula: {X-0OC-[(CH 2 )n-COO]m )p-Y (1) 15 wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, pis I or 2, 20 m is 0 or 1, and n is an integer greater than or equal to 0. The lipophilic compound is preferably selected from the group consisting of ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, 25 and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In preferred embodiments, the sterol is cholesterol or sitosterol, the tocopherol is a (+)-tocopherol, the polyalkylene glycol is a polyethylene glycol or its methyl monoether having an average molecular weight between 400 and 1000, p is 30 equal to I or 2, m is equal to 0.or I and n is an integer between 2 and 18. 5 According to another aspect of the invention, a water-soluble composition comprising a bioactive lipophilic compound and a solubilizing agent of the general formula
{X-OOC-[(CH
2 )n-COO1m~p-Y 5 wherein: p is 1 or 2, m is 0 or 1, and n is an integer in the range 0 n 18 X is a residue of a hydrophobic moiety selected from the group 10 consisting of cholesterol, 7-dehydrocholesterol, campesterol, sitosterol, ergosterol, stigmasterol, and a-,D-, y-, and A tocopherols and derivatives thereof, Y is a residue of a hydrophilic moiety,selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, is polyamines, polysaccharides, polyhydroxy compounds, polylysines and derivatives thereof, provided that: when p and m are equal to 1 and the hydrophobic moiety is (+)-c-tocopherol, n is not equal to 2. 2o According to another aspect, the invention provides a method of preparation and purification of a water-soluble composition comprising a solubilizing agent of the general formula (1), in the presence or in the absence of an auxiliary organic solvent. The solubilization is achieved by dissolving a water-insoluble lipophilic compound and a solubilizing agent in a water-miscible organic solvent, diluting 25 the solution with water, and removing the organic solvent and optionally a part of water under reduced pressure. Alternatively, a lipophilic compound and solubilizing agent can be admixed directly in a predetermined molar ratio and heated to a temperature higher than the their respective melting points, to form a water-soluble composition in the form of a clear melt, which can be then diluted with an aqueous solution to a desired concentration. The water-soluble composition may be additionally purified by dissolving it in a small amount of water, heating the solution until the composition separates as a clear liquid phase, and removing the separated composition from the solution while 5 keeping the temperature of the solution substantially unchanged. According to still another aspect, the invention provides pharmaceutical or cosmetic formulations comprising a water-soluble composition of a lipophilic compound and a solubilizing agent of formula (1). 10 According to yet another aspect, the invention provides novel solubilizing agents of formula (1) and methods of their preparation and purification. According to a further embodiment of the invention, a method is provided 15 for the treatment of a fungal infection in humans or warm-blooded animals in need of such treatment, comprising administering to such human or warm blooded animal, a therapeutically effective amount of a water-soluble composition, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and 20 polyoxyethanyl-a-tocopheryl sebacate, and a macrolide polyene antibiotic , formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, or 3:1 to 4:1, in conjunction with a pharmaceutically effective carrier or excipient. According to a yet further embodiment of the invention, a water-soluble 25 composition is provided, comprising, a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl cholesteryl sebacate and polyoxyethanyl-a-tocopheryl sebacate, and a macrolide polyene antibiotic, formulated in a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, or 3:1 to 4:1. 30 7 2652451 _I (GHMattcrs) P50274.AU.2 27104/11 According to a still further embodiment of the invention, a method is provided for preparing a water-soluble composition, comprising the steps of, (a) dissolving the antibiotic and the solubilizing agent in a water 5 miscible organic solvent, In a weight ratio of solubilizing agent to antibiotic of 2:1 to 4:1, (b) removing from the solution the organic solvent to achieve a desired concentration of the water soluble composition, (c) dissolving the composition in water, and 10 (d) drying. According to a yet further embodiment of the invention, a method is provided for delivery of a-tocopherol to humans or warm-blooded animals in 15 need thereof, comprising administering to such human orwarm-blooded animal, an effective amount of a water-soluble form of vitamin E. PTS is a water-soluble form of vitamin E. We have found that in the body of an animal, water-soluble forms of vitamin E, such as PTS, get hydrolysed and 20 are systemically converted back to x-tocopherol, an active non-toxic form of vitamin E. Accordingly, PTS can itself be administered to an animal in need thereof, as a means for delivery of active non-toxic vitamin E. According to a yet further embodiment of the invention, a water-soluble 25 composition is provided, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl-cholesteryl sebacate and polyoxyethanyl-a-tocopheryl sebacate, and a compound having a high content of polyunsaturated fatty acids and derivatives thereof. Derivatives include mono-, di- and tri- glycerides and their aliphatic esters. Examples of 8 such compounds include fish oils, plant oils and other plant extracts. Further examples of such compounds can be found in the literature in B. Fitch Haumann: Alternate Sources for n-fatty acids in: Inform - International news on fats, oils and related materials (1998) vol. 19 no. 12, p. 1108, and in G. 5 Fernandes et al. Role of omega-3 fatty acids in health and disease. In: Nutrition Research (1993) vol. 13, 19-45, the disclosures of which are incorporated herein by reference. In one specific embodiment, there is provided a water-soluble composition, comprising io (a) a solubilizing agent selected from the group consisting of (i) polyoxyethanyl-sitosterol sebacate (PSS) and (ii) polyoxyethanyl-a-tocopheryl sebacate (PTS), and (b) a compound having a high content of polyunsaturated fatty acids. According to a still further embodiment of the invention, a water-soluble 15 composition is provided, comprising a solubilizing agent selected from the group consisting of polyoxyethanyl-sitosterol sebacate, polyoxyethanyl cholesteryl sebacate and polyoxyethanyl-a-tocopheryl sebacate, and a bioactive lipophilic compound selected from the group consisting of a terpene and a terpenoid. 20 We have now solubilized in water a-tocopheryl acetate, a synthetic form of vitamin E, using various solubilizing agents including PTS-600 and PTS-400. The ratio of solubilizing agents to a-tocopheryl-acetate was in the range of 2:1 to 5.5:1 w/w. Water-soluble compositions were obtained using either the 25 awaiting solvent eg THF method, or the direct admixing method described above. Tocotrienols are water-insoluble tocopherol derivatives, useful as antioxidants. We have now made a pegylated form of a tocotrienol polyoxyethanyl tocotrienyl sebacate (PTrienS-600), which is useful as a 30 solubilizing agent. The method involves dissolving a tocotrienol and triethylamine in a water-misable organic solvent e.g. ethyl acetate, and reacting the solution with sebacoyl chloride, followed by pegylation. See examples 31 and 32. It will be appreciated that this invention is also applicable to other tocotrienols such as those described in www.eastman.com/online publications, 35 Nutriene tocotrienols. Publication v-24, (1998), the disclosure of which is incorporated herein by 9 2476074_1 (GHMaters) P50274 AU.I reference. We have also dissolved the tocotrienols in water, using a solubilizing agent eg. PTS-600 or a pegylated tocotrienols polyoxycthanyltocotrienyl sebacate eg (PtrieneS-600.) (see example 32). The ratio of solubilizing agent to tocotreinols is about 5.5:1 w/w. The water-soluble compositions are obtained 5 using either the auxiliary solvent method, or the direct admixing methods described above. We have also shown that CoQ 1 0 can be water solublized using either PTS-400, or pegylated derivatives of tocotrienols, such as 10 polyoxyethanyltocotrienyl sebacate (PtriensS-600) as solubilizing agent. The ratio of solubilizing agent to CoQ 10 was in the range 2.5:1 to 3.5:1. The direct admixing method described above was used. See example 33. BRIEF DESCRIPTION OF THE DRAWINGS 15 Fig. 1 is a graph showing the toxicity of various solubilizing agents. Fig. 2 is a graph showing the bioavailability of CoQ 10 in various water-soluble compositions. 20 Fig. 3 is a graph showing the effect of PTS-CoQ 1 o composition on cellular ATP level in NT2 cells. Fig. 4 is a graph showing the protective effect of PTS-CoQ1o composition against 25 hypoxia in NT2 cells. Fig. 5 is a graph showing the effect of PTS-CoQ 1 0 and PTS-Vitamin E compositions on the viability of hypoxia-treated NT2 cells. 30. DETAILED DESCRIPTION OF THE INVENTION 10 The invention provides a method of solubilization of substantially water insoluble, bioactive lipophilic compounds, by providing a water-soluble composition comprising the lipophilic compound and a solubilizing agent of the 5 following general formula:
{X-OOC-[(CH
2 )n-COO]m }p-Y (l) wherein: 10 X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m isO or 1, and n is an integer greater than or equal to 0. 15 The hydrophobic moiety of the solubilizing agent is a hydrophobic (lipophilic) molecule having an esterifiable hydroxy group e.g. a sterol or aX tocopherol, in particular cholesterol, 7-dehydrocholesterol, campesterol, sitosterol, ergosterol, stigmasterol, or an a-, P-, y-, or A-tocopherol. Cholesterol 20 and sitosterol are preferred sterols, sitosterol being particularly preferred. ca-(+) tocopherol and a-(±)-tocopherol are exemplary tocopherols, a-(+)-tocopherol (vitamin E) being preferred. The residue of the hydrophobic moiety is the entire hydrophobic molecule, except for its esterified hydroxy group, such as 3-p hydroxy group of cholesterol or sitosterol or 6-hydroxy group of cx-tocopherol. 25 The hydrophilic moiety of the solubilizing agent is a hydrophilic molecule having an esterifiable hydroxy or carboxy group, for example, selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, polyamines, polysaccharides, polyhydroxy compounds, 30 polylysines, and derivatives thereof. Of those, polyethers are preferred, polyalkylene glycols being particularly preferred. The term "polyalkylene glycol" 11 includes polymers of lower alkylene oxides; in particular polymers of ethylene oxide (polyethylene glycols) and propylene oxide (polypropylene glycols), having an esterifiable hydroxy group at least at one end of the polymer molecule, as well as derivatives of such polymers having esterifiable carboxy groups. The 5 residue of the hydrophilic moiety is the entire hydrophilic molecule, except for its esterified hydroxy or carboxy group or groups, such as terminal hydroxy groups of a polyethylene glycol molecule. Suitable polyethylene glycols may have a free hydroxy group at each 10 end of the polymer molecule, or may have one hydroxy group etherified with a lower alkyl, e.g., a methyl group. Also suitable for the practice of the invention are derivatives of polyethylene glycols having esterifiable carboxy groups. Polyethylene glycols are commercially available under the trade name PEG, usually as mixtures of polymers characterized by an average molecular weight. 15 Polyethylene glycols having an average molecular weight from about 300 to about 5000 are preferred, those having an average molecular weight from about 600 to about 1000 being particularly preferred. Compounds of formula (1) for which m is equal to 1 can be regarded as 2o diesters of an alkanedioic acid of the general formula HOOC-(CH 2 )n-COOH. For the practice of the present invention, alkanedioic acids with n from 0 to 18 are preferred, those with n from 6 to 10 being particularly preferred. Sebacic acid (n=8) is most particularly preferred. 25 Bioactive lipophilic compounds which can be solubilized using solubilizing agents of the present invention belong to a variety of therapeutic and chemical categories and include ubiquinones, ubiquinols, sterols, vitamins, provitamins and macrolide polyene antibiotics. 30 Preferred ubiquiniones and ubiquinols are those of the formula: 12 R H wherein R is
CH
3 O OH
CH
3 0 CH 3
CH
3 0 CH 3 or
CH
3 0
CH
3 0 0 - OH and k is an integer of from 6 to 12. Those with k equal to 10 (ubiquinohe-50 or Coenzyme Q10 and ubiquinol-50 or reduced Coenzyme Q10, respectively) are particularly preferred. 5 Cholesterol, sitosterol, ergosterol and 7-dehydrocholesterol are preferred sterols. Vitamins A, D, E, and K are preferred vitamins and provitamin A (p carotene) is a preferred provitamin. Amongst macrolide polyene antibiotics, amphotericin-B, nystatin, and candicidin are preferred. 10 The water-soluble compositions of the present invention contain a bioactive lipophilic compound and a solubilizing agent in a molar ratio of approximately 1:1 to 1:5. The molar ratio of about 1:2 is preferred. The upper limit of the molar ratio is not critical, and the solubilizing agent can be used in 15 any excess. This is not desirable, however, as increasing the amount of the solubilizing agent decreases the concentration of the active ingredient in the composition and in. its aqueous solutions. The water-soluble compositions of the present invention can be prepared 20 by two different procedures, either in the presence or in the absence of an auxiliary organic solvent. In the first case, a lipophilic compound and a solubilizing agent are first dissolved in a predetermined molar ratio in a water miscible organic solvent and this solution is then diluted with a predetermined amount of water, without precipitation of the lipophilic compound. The organic 25 solvent and water are then removed by evaporation under reduced pressure, A volatile organic solvent is usually removed first, followed by water, in which case 13 the amount of water removed from the solution may be controlled, to achieve a desired concentration of the water-soluble composition in the remaining concentrate. Alternatively, both the organic solvent and water are removed by evaporation, and the waxy residue is reconstituted with a suitable aqueous 5 medium (such as water, physiological saline, or a buffer solution), to provide a clear.aqueous solution. The organic solvent used is in the above procedure should be a good solvent for both the lipophilic compound and the solubilizing agent and has to be 10 miscible with water. If a water-soluble composition is to be used in a pharmaceutical formulation, this solvent should be also pharmaceutically acceptable, as the removal of the solvent by evaporation may not always be possible. Examples of solvents suitable for the practice of the invention are tetrahydrofuran, ethanol, ethylene glycol, propylene glycol, and acetic acid. 15 Solvents with a low boiling point, such as tetrahydrofuran, are preferred. The amount of the organic solvent is not critical, and is equal to or greater than the minimum amount of solvent necessary to dissolve the given amounts of the lipophilic compound and solubilizing agent. The amount of water used forthe 20 dilution is also not critical, and is preferably between 10 to 25 times the volume of the organic solvent. An alternative procedure for preparing water-soluble compositions according to the invention consists of preparing first a mixture of a lipophilic 25 compound and a solubilizing agent in a predetermined molar ratio. This mixture is then heated to a temperature higher than the respective melting points of the lipophilic compound and the solubilizing agent, for a time necessary to obtain a clear melt, which process can be seen as a dissolution of the lipophilic compound in the solubilizing agent. The melt so obtained can be reconstituted 30 with a predetermined amount of a suitable aqueous medium, to provide a clear aqueous solution of a desired concentration. This method of preparing water 14 soluble compositions of the invention is preferred, as it is simpler and avoids limitations of the procedure that relies on an auxiliary organic solvent, such as the pharmaceutically acceptable character of the solvent required for most applications. 5 The ability of solubilizing agents of the present invention to dissolve lipophilic compounds in the absence of an auxiliary organic solvent can be used for preparing water-soluble forms of bioactive compounds, in particular Coenzyme Q 10 , without purifying it by crystallization after synthesis, thus 10 reducing the overall cost of preparing water-soluble compositions of this compound. Many compositions of the present invention show a decreasing solubility in water with increasing temperature of the solution. This provides an alternative is method of isolation and/or purification of such compositions. For the purpose of purification, the composition is dissolved in water at a ratio of the composition to water not exceeding 1:2 by volume and the solution is heated, for example in a boiling water bath, for a time necessary to achieve the separation of the water soluble composition as a liquid phase, usually a few minutes. The oily phase is 20 then separated from the hot solution, while keeping the temperature of the solution substantially unchanged, as cooling of the solution would increase the solubility of the composition and result in a reduced yield of the recovery. A speedy separation of the oily phase to avoid the cooling can be achieved, for example, by centrifugation. 25 The water-soluble compositions of the present invention have a waxy consistence and may be difficult to manipulate in this highly concentrated form. To make them more easily processable as solids, they may be combined with a suitable solid, water-soluble additives, such as vitamin C, gelatin, a protein 30 supplement, or a polyethylene glycol. In the latter case, a polyethylene glycol having an average molecular weight greater than about 5000 is preferred. The 15 ratio of the composition and the additive is not critical, but will be usually limited to avoid an unnecessary dilution of the active ingredient by the additive. Such solid composition are particularly useful for the preparation of certain dosage forms of bioactive compounds, such as tablets or granulates. 5 The compositions of the present invention show an excellent solubility in water and allow the preparation of aqueous solutions of almost any concentration. As the concentrated solutions can be diluted with an aqueous medium in any proportion and over a wide range of pH conditions without 10 precipitation of the lipophilic compound, the solubility of the compound is maintained under physiological conditions, for example after an oral or parenteral administration of the composition. This normally results In an improved bioavailability of the compound. 15 The compositions of the present invention and aqueous solutions thereof show an excellent stability over long periods of time (several months at room temperature, at least one year when refrigerated, or indefinitely when frozen) and over wide ranges of temperature and pH conditions (temperatures from 800C to 1200C, pH from 2.0 to 8.0). Aqueous solutions can be repeatedly frozen 20 and thawed without any perceptible degradation. The stability under high temperature conditions allows an easy sterilization of the solutions, without compromising the solubility of the active ingredient. The water-soluble compositions of the present invention can be easily 25 incorporated into pharmaceutical or cosmetic formulations, which are then charcterized by an improved bioavailability of the lipophilic active ingredient. Such formulations may further contain additional active ingredients and/or a pharmaceutically or cosmetically acceptable additives or vehicles, including solvents, adjuvants, excipients, sweeteners, fillers, colorants, flavoring agents, 30 lubricants, binders, moisturizing agents, preservatives and mixtures thereof. The formulations may have a form suitable for a topical (e.g., a cream, lotion, gel, 16 ointment, dermal adhesive patch), oral (e.g., a capsule, tablet, caplet, granulate), or parenteral (e.g., suppository, sterile solution) administration. Among the acceptable vehicles and solvents that may be employed for administration by injection are water, mildly acidified water, Ringer's solution and isotonic sodium 5 chloride solution. Among water-soluble compositions and pharmaceutical and cosmetic formulations, those comprising Coenzyme Q1o are of particular interest. Coenzyme Q,0 is a natural compound whose therapeutic potential has been 10 recently recognized for a number of conditions and disorders related to mitochondrial dysfunctions and/or tissue damage caused by free radicals and oxidants. These include, but are not limited to: cardiovascular diseases (e.g., congestive heart failure), muscular disorders (e.g., muscular dystrophy), mitochondrial encephalomyolopaties (i.g., MELAS, KSS), neurodegenerative is disorders (e.g., Alzheimer', Parkinson's, Huntington's diseases), restoration of immune deficiencies caused by drugs or infections (AIDS, allergies, cancer). Of particular interest is the clinical use of Coenzyme Q 1 0 to minimize tissue damage resulted from ischemia/reperfusion (e.g., stroke, head trauma, angioplasty, organ transplantation, surgery in general). Another area of interest is the use of 20 Coenzyme Q10 in therapy as adjuvant, for example for infectious diseases, in combination with cholesterol-lowering drugs for the treatment of hypercholesteremia, or in combination with chemotherapeutic agents in the treatment of cancers. Coenzyme Q10 is also of great interest to cosmetic industry, as an agent slowing down natural skin ageing processes. Water-soluble 25 compositions comprising a macrolide polyene antibiotic, such as amphotericin-B, nystatin, or candicidin, are of particular interest for the treatment of fungal infections, including fungal infections in immunocompromised patients. Bioactive lipophilic compounds in the form of a water-soluble composition 30 according to the present invention may be administered to a warm-blooded animal, particularly a human, in need of the prophylaxis or therapy. The dose of 17 a bioactive lipophilic compound and the corresponding dose of its water-soluble composition for treating the above-mentioned diseases or disorders vary upon the manner of administration, the age, sex, the body weight of the subject, and the condition being treated, and will be ultimately decided by the attending 5 physician or veterinarian. Such an amount of the bioactive compound in the form of its water-soluble composition as determined by the attending physician or veterinarian is referred to herein as a "therapeutically effective amount". The biological activity of Coenzyme Q 1 0 is believed to be linked to its 10 ability to act as an antioxidant and free radical scavenger protecting integrity of cell membranes and to offset the inability of diseased cells to manufacture sufficient energy for cellular repair, by stimulating the mitochondrial respiration and production of ATP. For effectiveness in both clinical and cosmetic applications, preparations of Coenzyme Q 1 0 with high bioavailability and solubility 15 in aqueous media are normally desirable. Most pharmaceutical and cosmetic formulations proposed to date for Coenzyme Q 1 0 suffer from a number of drawbacks, such as the use of components causing an undesirable immune response when administered 20 parenterally or gastric disorders when administered orally. Some formulations are stable only over a narrow range of pH values and most are characterized by a poor bioavailability of the active component (Coenzyme Q10). In particular, there are no reliable formulations for intravenous administration of Coenzyme
Q
10 , as there are no formulations universally applicable to topical, oral, and 25 parenteral administration routes. The water-soluble compositions of the present invention comprising Coenzyme Q 10 are free of the above drawbacks and can be incorporated into pharmaceutical formulations suitable for all administration routes, topical, oral, and parenteral, which are stable and characterized by a good solubility and bioavailability of the active component. 30 The invention further provides novel solubilizing agents of the general 18 formula
{X-OOC-[(CH
2 )n-COO]m)p-Y (l) 5 wherein: p is 1 or2, m is 0 or 1, and n is an integer in the range of Osns18, X is a residue of a hydrophobic moiety selected from the group consisting of cholesterol, 7-dehydrocholesterol, 10 campesterol, sitosterol, ergosterol, stigmasterol, and a-,p-, y-, and A-tocopherols and derivatives thereof, Y is a residue of a hydrophilic moiety, selected from the group consisting of polyalcohols, polyethers, polyanions, polycations, polyphosphoric acids, polyamines, 15 polysaccharides, polyhydroxy compounds, polylysines and derivatives thereof, provided that: 20 - when p and m are both equal to 1 and the hydrophobic moiety is a-(+) tocopherol, n is not equal 2, Compounds excluded by the proviso are known in the prior art, in particular polyoxyethanyl-cholesteryl sebacate (PCS) and polyoxyethanyl-at 25 tocopheryl succinate (TPGS). However, PCS was only disclosed previously as a solubilizing agent for CoQ 1 o, that is, in our previously published PCT application no. W096/17626. The compounds of formula (1) can be prepared by standard methods of 30 synthetic organic chemistry, well known to those skilled in the art. In particular, compounds where p is equal to 1 or 2 and m is equal to 1 can be prepared by 19 reacting a compound of the general formula X-OH with a compound of the general formula Z-OC-(CH 2 )n-CO-Z, where Z is a leaving group, and further reacting the product so obtained with a compound of the general formula HO-Y OR, wherein R is hydrogen or an alkyl, and X, Y and n are as defined 5 hereinbefore. Halogens, in particular Cl and Br, are preferred as the leaving group Z. Hydrogen and a lower alkyl (Ci - C 4 ) are preferred for R. Many solubilizing agents of formula (I) show a decreasing solubility in water with the increasing temperature of the solution, which provides a 10 convenient method of purification of these compounds. The steps and conditions of the purification process are substantially the same as those discussed above for the purification of water-soluble compositions of the invention. Various aspects of the present invention will be further illustrated by the 1s following non-limiting examples. EXAMPLES. The following abbreviations are used throughout the Examples: 20 CoQ10, CoQ 1 0 - Coenzyme Q 1 0 PCS - polyoxyethanyl-cholesteryl sebacate PTS - polyoxyethanyl-a-tocopheryl sebacate PSS - polyoxyethanyl-sitosteryl sebacate 25 PTD - polyoxyethanyl-a-tocopheryl dodecanodioate PTSr - polyoxyethanyl-a-tocopheryl suberate PTAz - polyoxyethanyl-a-tocopheryl azelaate TPGS - polyoxyethanyl-a-tocopheryl succinate 30 A number following one of the above abbreviations (e.g., PCS-600) indicates an average molecular weight of the polyoxyethanyl moiety of the compound. A 20 number followed by Me abbreviation (e.g., PTS-750Me) indicates a polyoxyethanyl moiety capped with a methyl group (methoxypolyoxyethanyl). Examples 1 and 2 illustrate methods of preparation of solubilizing agents 5 of the present invention. Example 1. Preparation of polyoxyethanyl-sitosteryl sebacate (PSS-600) 0.83 g of b-sitosterol (Sigma Chem. Co., product #S-5753, approximately lo 60%) was dissolved in 3 ml of dry toluene at 400C, followed by addition of 1.33 mmole of triethylamine (TEA). 1.33 mmole of sebacoyl chloride dissolved in 2 ml of dry toluene was than added (dropwise, while stirring, and under anhydrous conditions) to the b-sitosterol-TEA solution. The reaction was carried out for 10 min at room temperature, at which time 2 mmole of PEG-600 (polyethylene 15 glycol, Sigma Chem. Co.; product # P-3390) and 2.66 mmole of TEA dissolved in 3 ml of dry toluene were added dropwise to the reaction mixture. The reaction was continued with stirring for additional 20 min at room temperature and the reaction mixture was extracted four times with 3 ml each time of saturated solution of NaCl. The toluene was removed under reduced pressure leaving a 20 waxy residue. This product was dissolved in 15 ml of water and water-insoluble materials removed by filtration. The filtrate was lyophilized, yielding 0.8 g of pale - yellow waxy product (PSS-600). The same method was used for the preparation of polyoxyethanyl-cholesteryl sebacate (PCS-600). Example 2. Preparation of polyoxyethanyl-a-tocopheryl sebacate (PTS 25 600) A solution of 1 mmole of a-tocopherol (Sigma Chem. Co., product # T 3251) and 1.33 mmole of TEA in 3 ml of dry toluene was added (dropwise, under anhydrous conditions, while stirring) to 1.33 mmole of sebacoyl chloride 3o dissolved in 2ml of dry toluene. The reaction was carried out for 10 min at room temperature, followed by a dropwise addition of 2 mmole of PEG-600 21 (polyethylene glycol, Sigma, P-3390) and 2.66 mmole of TEA dissolved In 3 ml of toluene. The reaction was continued for additional 20 min at room temperature with constant stirring. The reaction mixture was extracted four times with 3 ml each time of saturated solution of NaCl and toluene evaporated under 5 a reduced pressure. The product was dissolved in 5 ml of water and the residual toluene was further removed by co-evaporation with water under a reduced pressure. The final waxy product (1.15 g) was obtained by lyophilization. Other solubilizing agents (Table 1) were obtained by linking polyethylene 10 glycol (average molecular weight 1000, Sigma Chem. Co., product# P-3515) or methoxypolyethylene glycol (average molecular weight 750, Sigma Chem. Co., product # M-7018) to a-tocopherol using adipoyl, suberoyl, azelaoyl or dodecanedioyl dichlorides. They were synthesized according to the method of Example 2 and their identities were confirmed by mass spectrometry analysis 15 applying MALDI-TOF technique. Example 3 provides molecular characteristics of the synthesized solubilizing agents. 20 22 Example 3. Molecular characteristic of solubilizing agents obtained by MALDI-TOF mass spectrometry. Table 1. Molecular mass of synthesized solubilizing agents. Solubilizing agent Molecular mass m/z PSS-600 1194.3 ± 44 PCS-600 1166.1 ±44 PTS-600 1209.7± 44 PTD-600 1237.5 ± 44 PTS-750Me 1355.7 ± 44 PTD-750Me 1383.7± 44 PTS-1000 1605.9 ± 44 PTSr-600 1181.6 ± 44 PTSr-1000 1578.2 ± 44 PTAz-600 1195.8 ± 44 PTA-600 1153.5 ± 44 PTSc-600 1125.7 ±44 PTS-400 1009.7 ±44 5 23 Example 4 illustrates a method of purification of solubilizing agents. Example 4. Purification of solubilizing agents. 5 A solubilizing agent prepared according to Examples I or2was dissolved in water at 2:1 v/v ratio. The solution was heated in a boiling water bath for approximately 2 min, until a visible precipitation occurred. This was followed by a brief centrifugation (at least 2000xg) of the hot mixture to achieve separation of 10 the precipitated product which is insoluble in hot water. The water phase (supernatant ) was removed by decantation leaving a clear pellet of the product containing approximately 10% of water. Examples 5 and 6 illustrate a preparation of water-soluble Coenzyme Q10 15 compositions by a direct admixing of the two components. Example 5. Direct preparation of tocopherol-based water-soluble compositions of Coenzyme Q 10 . 20 24 Table 2. Components of tocopherol-based water-soluble Coenzyme Q 1 0 compositions. Coenzyme Q 10 0.01 g TPGS 0.035 g Coenzyme Q 10 0.01 g PTS-600 0.03 g Coenzyme Q 10 0.01 g PTD-600 0.03 g Coenzyme Q 10 0.01 g PTS-750Me 0.03 g Coenzyme Q 10 0.01 g PTD-750Me 0.03 g Coenzyme Q 10 0.01 g PTS-1 000 0.03 g Coenzyme Q10 0.01 g PTSr-1000 0.03 g Coenzyme Q 10 0.01 g PTSr-600 0.03 g Coenzyme Q1o 0.01 g PTAz-600 0.03 g 25 Table 2 shows amounts of starting materials used for the preparation of a tocopherol-based water-soluble compositions of Coenzyme Q1o. In each case the two components were admixed together at a predetermined ratio and were 5 heated to a temperature higher than their melting points, typically 60*C-80 0 C, until the components melted together and formed a clear, transparent and uniform melt. The optimal ratio of a solubilizing agent to Coenzyme Q 1 0 was found to be 2:1 mol/mol or 3:1 w/w. These compositions could be stored in sealed vials for at least 2-3 years when refrigerated. They could be 10 reconstituted at any time with water or physiological solution of saline (0.9%), at any ratio, and they remained water soluble and stable for several month when refrigerated or frozen. Example 6. Direct preparation of sterol-based water-soluble compositions 15 of Coenzyme Q 10 . Table 3. Components of sterol-based water-soluble Coenzyme Q 10 compositions Coenzyme Q 10 0.01 g PCS-600 0.03 g Coenzyme Q 10 0.01 g PSS-600 0.03 g 20 Table 3 shows amounts of starting materials used for the preparation of sterol-based, water-soluble compositions of Coenzyme Q 1 0 . In each case the two components were admixed at a predetermined ratio (the optimal ratio of a solubilizing agent to CoQ10 was found to be 2:1 mol/mol or 3:1 w/w) and were heated to a temperature higher than their melting points, typically 60*C-80 0 C, 26 until the components melted together and formed a clear transparent liquid. The liquid was dissolved in water (at a ratio 2:1 v/v) and the solution was heated in a boiling water bath for approximately 2 minutes, until clear waxy precipitate was formed. The precipitate could than be separated from the hot solution by 5 centrifugation at 2000xg. To achieve its full water solubility at room temperature, the cycle of heating, centrifugation and cooling to room temperature, without removal of supernatant between the cycles, was repeated 2 to 3 times. After the final centrifugation, the hot supernatant was decanted and clear transparent pellet of the product was recovered. The compositions could be 10 stored refrigerated in sealed vials for at least 2-3 years. Aqueous solutions (in water or saline) of the above compositions could be prepared and they were stable for several months when refrigerated. Examples 7, 8 and 9 illustrate preparation of water-soluble Coenzyme 15 Q10 compositions in the presence of an auxiliary solvent. 27 Example 7. Solvent-based preparation of water soluble compositions of Coenzyme Q 10 . Table 4. Components of water-soluble compositions of Coenzyme Q 10 . Coenzyme Q 10 5 g PCS-600 15 g THF 30 ml
H
2 0 400 ml Coenzyme Q1o 0.01 g PSS-600 0.03 g THF 0.1 ml
H
2 0 2.5 ml Coenzyme Q 10 0.3 g PTS-600 1 .0 g THF 4.0 ml
H
2 0 60.0 ml Coenzyme Q 10 0.01 g PTD-600 0.03 g THF 0.1 ml
H
2 0 2.5 ml Coenzyme Q 10 0.01 g PTS-750Me 0.03 g THF 0.1 ml
H
2 0 2.5 ml Coenzyme Q 10 0.01 g PTD-750Me 0.03 g THF 0.1 ml
H
2 0 2.5 ml 5 28 Table 4 shows amounts of starting materials used for various water soluble Coenzyme Q 10 compositions. In each case Coenzyme Q 10 and a solubilizing agent were both dissolved in tetrahydrofuran (THF) and the solution was added to water with vigorous stirring, while maintaining the temperature of 5 the mixture close to 0 0 C. The solvent and a part of water were then evaporated under a reduced pressure to obtain a desired concentration of Coenzyme Q 10 , usually 80-100 mg /ml. These compositions could be stored refrigerated for at least 2-3 years and could be reconstituted with aqueous media (water, saline) to a desired final concentration of Coenzyme Q 10 in the water-soluble form. 10 Compositions with higher concentrations of Coenzyme Q1 0 (up to 200mg/ml) were also obtained by following this procedure. Example 8. Solvent-based preparation of water-soluble TPGS - Coenzyme 15 Q 1 0 composition. Table 5. Components of water-soluble TPGS-Coenzyme Q 10 composition. Coenzyme Q1o 0.01 g TPGS 0.035 g THF 0.1 ml
H
2 0 2.5 ml Table 5 shows amounts of starting materials used for water-soluble 20 TPGS-Coenzyme Q 1 0 composition which was prepared according to the procedure described in Example 7. However, this product did not precipitated from an aqueous solution after heating. Water and the solvent could be removed by evaporation under a reduced pressure. Water solubility and stability of the composition was the same as those described in Examples 4 and 25 5. 29 Example 9 describes a procedure for the preparation of water-soluble ubiquinol compositions. Example 9. Preparation of water-soluble ubiquinol compositions. 5 Table 6. Components of water-soluble ubiqulnol compositions. Ubiquinol 50 0.3 g TPGS 0.9 g Ubiquinol 50 0.3 g TPGS 0.9 g Propylene Glycol usp. 0.9 ml Ubiqulnol 50 0.1 g Coenzyme Q 10 0.1 g PTS-600 0.5 g Ubiquinol 50 0.1 g Coenzyme Q 10 0.1 g Vitamin E 0.001 g PTS-600 0.5 g Table 6 shows amounts of starting materials used for water-soluble 10 ubiquinol (a reduced form of Coenzyme Q 10 ) compositions. Ubiquinol was first prepared by the following method. 0.3 g of Coenzyme Q 10 and 0.2 g of zinc dust were suspended in 2.5 ml of glacial acetic acid. The mixture was placed in 50 0 C water bath, with occasional shaking, for approximately 15 min. The reaction mixture was diluted with 2.5 ml of water and extracted twice with 5 ml of hexane. 30 The hexane extracts were combined, washed twice with 2.5 ml of water, dried over anhydrous magnesium sulfate, evaporated under reduced pressure and finally under a high vacuum. The resulting white waxy residue of ubiquinol was combined with 0.9 g of TPGS and it was heated to 60"C-80*C until the mixture 5 melted and became clear. Upon reconstitution with water an opaque solution was formed. This composition remained unchanged for up to 2 months when sealed under argon and frozen. The water solubility of this composition could be improved by admixing with propylene glycol at a ratio given in the Table 6. The aqueous (water and saline) solutions of this composition were stable and could 10 be stored sealed under argon when frozen. Examples 1.0 and 11 illustrate preparation of water soluble vitamin E and p-carotene compositions. 15 31 Example 10. Preparation of water-soluble formulations of vitamins. Table 7. Components of water-soluble compositions of vitamin E and p carotene. Vitamin E 0.10 g PTS-600 0.60 g Vitamin E 0.22 g PCS-600 1.00 g THF 2.50 ml
H
2 0 35.00 ml Vitamin E 0.025 g PTS-600 0.150 g THF 0.125 ml
H
2 0 2.0 ml Provitamin A (p-carotene) 0.01 g PTS-600 0.05 g THF 0.20 ml
H
2 0 3.0 ml Table 7 shows amounts of starting materials used for various compositions prepared by direct admixing method (Example 5) orwith the aid of an auxiliary solvent (Example 7). The optimal ratio of a solubilizing agent to 10 Vitamin E was found to be 2:1 mol/mol or 6:1 w/w. The concentrated compositions could be stored refrigerated for up to 2 years. The aqueous solutions (in water or saline) were also stable and could be stored frozen. Example 11 illustrates methods for isolation, concentration and 15 sterilization of the compositions according to the present invention. 32 Example 11. Isolation, concentration and sterilization of water-soluble compositions. According to the present invention, two processes can be applied for the 5 preparation of water-soluble compositions of lipophilic compounds: (i) a lipophilic compound and a solubilizing agent can either be combined directly and melted together, or (ii) the two are first dissolved in a water-miscible auxiliary solvent, the solution mixed with water and both the solvent and the excess of water are removed by evaporation. The obtained compositions are soluble in aqueous 10 media at room temperature, but not at temperatures higher than approximately 80 0 C. They precipitate out of water when heated, but return to the solution upon cooling. This provides a simple, effective and inexpensive method of their isolation, concentration and sterilization. 15 Typically, the aqueous solutions of the compositions (with the exception of TPGS-Coenzyme Q 1 0 , Example 9) are heated in a boiling water bath for about 2 min or until visible precipitate is formed. The separation of the precipitates from the hot water is accelerated by a rapid centrifugation at 2000xg. The water phase is decanted and the obtained waxy, transparent composition can be 20 stored refrigerated in sealed vials. It remains stable for at least 8 month and can be further diluted with aqueous media (water, saline or a buffer). When refrigerated, these solutions are stable for at least 3 years. The process of precipitation/solubilization is reversible and repeating it several times improves the stability of diluted aqueous solutions of the composition. If precipitation of 25 the composition occurs during storage, its solubility can be restored by applying the above heating/centrifugation cycle. The compositions are also suitable for injections, since the described process can be applied for their sterilization. Example 12 illustrates the preparation of dry powder compositions 30 containing Coenzyme Q 10 . 33 Example 12. Preparation of dry powder Coenzyme Q 10 compositions. Table 8. Components of dry powder Coenzyme Q 10 compositions. CoQIO/PCS-600 composition containing 0.07 g CoQIO/0.21 g PCS-600 40 mg of CoQI 0/ml of water BSA (0.25 g/ml of water) 0.25 g CoQ1O/PCS-600 composition 0.07 g CoQ10 / 0.21 g PCS-600 containing 40 mg of CoQ1O/ml of water Gelatin (0.125 g/ml in water) 0.25 g CoQ1O/PCS-600 composition 0.03 g CoQ10 / 0.09 g PCS-600 containing 40 mg of CoQIO/ml of water Vitamin C (0.25 g/ml in water) 0:50 g 5 Table 8 shows amounts of starting materials used for the preparation of dry powder compositions of Coenzyme Q 10 . The aqueous solutions of the above components were combined and lyophilized. The resulting powdered products could be pressed into tablets which remained stable and water-soluble. 10 Example 13 illustrates the preparation of dry powder compositions containing multiple components. 34 Example 13. Preparation of compositions containing Coenzyme
Q
1 0 , vitamin E and vitamin C. Table 9. Components of water soluble complex compositions. Coenzyme Q10/PTS-600 composition 0.03 g CoQ10 /0.09 g PTS-600 (containing 40 mg of CoQ10/mi of water) Vitamin E/PTS-600 composition (containing 20 mg of vitamin E/ml) 0.005 g Vit E / 0.025 g PTS-600 Vitamin C (0.25 g/ml in water) 0.75 g 5 Table 9 shows amounts of starting materials used:The aqueous solutions of the above components were combined and lyophilized. The resulting powdered products could be pressed into tablets which remained stable and water-soluble. 10 Example 14 demonstrates the lack of toxicity of solubilizing agents. Example 14. In vitro toxicity study. 15 Stock solutions of solubilizing agents (I mg/ml in PBS) were prepared and were added directly to lymphocytic Jurkat and neuroblastoma NT2 cell cultures in the amounts required to achieve a final concentration in the medium of 200, 100 and 50 mg/ml and cell viability was assessed by trypan blue exclusion 20 assay. The results of assessment are shown in Fig. 1. With the exception of commercially available TPGS, none of the 35 solubilizing agents of the invention had adverse effects on either cell growth or viability in vitro when added to cell cultures at concentrations up to 200 mg/ml. Also. no toxicity was observed when the compositions containing CoQ1O and PTS, PCS or PSS were given to Sprague Dawley rats at concentrations up to 20 5 mg/kg body weight, as shown in Fig.2. Although no rationale can be provided to explain the toxicity of TPGS observed in the experimental paradigm used, its usefulness as a solubilizing agent in pharmaceutical formulations should be further investigated and should 10 be taken with caution. Example 15 illustrates improved bioavailability of water-soluble forms of CoQ10. 15 Example 15. Bloavallability of water-soluble forms of Coenzyme Q10. CoQ1O, in the form of either water-soluble or oil-soluble compositions, was administered by gavage to 300-350 g male Sprague Dawley rats at a dose of 6mg/kg body weight. Blood samples were collected and CoQ1 0 content was 20 measured in plasma by the HPLC method which we have developed for analysis of CoQ1O in biological samples (Graves et al., Analysis of CoEnzyme Q10 content in human plasma and other biological samples. In: Free Radicals and Antioxidant Protocols, Ed. D. Armstrong, Humana Press. pp: 353-365, 1998). 25 Briefly, 0.1 ml sample of plasma or lysed cells (Examples 15 and 16), was mixed with 0.33 ml of 1-propanol, vortexed for 30 sec and left to stand at room temperature for 1 min. 0.86 ml of n-hexane were than added, the sample was vigorously vortexed for 30 sec, and centrifuged to achieve a phase separation and to pellet the denatured proteins. The upper phase which consisted of n 30 hexane and 1 -propanol and contained CoQ 10 was collected and evaporated to dryness under argon. The remaining dry residue was redissolved in 60 ml of 36 ethanol and 2 ml of H 2 0 2 in order to convert all CoQ 1 O to its oxidized form. Sample aliquots were analysed by a reverse-phase chromatography on a Supelcosil LC-18-DB column (5 mm particle size, 30 cm x4.0 mm I.D.,Supelco) with the mobile phase of ethanol:methanol 80:20 (v/v) at the flow rate of 1 5 ml/min. Absorbance at 275 and 290 nm was monitored. A standard calibration curve of CoQIO and Beckman System Gold Software were utilized for data quantification. The amount of Coenzyme Q 10 was calculated according to measured peak-areas of analysed samples. The 10 calibration curve was prepared from a CoQ1 0 ethanol solution of a concentration determined spectrophotometrically from its extinction coefficient of 8=14,200 at 275 nm. The ethanol solution of CoQ1 0 can be stored in sealed amber vials at 20 0 C. The data presented in Fig. 2 show significantly improved (by 1.5 to 2 fold) is bioavailability of CoQ1O when given orally as a water soluble compositions in comparison with the oil formulation, Significantly, the kinetics of the uptake is much faster (plasma level peaked at about 3 hr) and the maximal plasma levels achieved are also much higher (by 2 fold) when CoQ10 is given in the water soluble form. 20 Example 16 illustrates the ability of cells to internalize the water-soluble form of CoQ10. 25 Example 16. Intracellular uptake of Coenzyme Q 10 . The following experiments were designed to demonstrate the ability of human keratinocytesto internalize exogenous CoQIO. Human skin keratinocytes (ATCC CRL-8858), were cultured in SFM (serum free medium, Gibco BRL, cat 30 no. 10724) supplemented with 0.2 ng/ml of EGF (epidermal growth factor), 30 mg/ml of bovine pituitary extract and different concentrations of CoQ1 0 which 37 was added directly to the tissue culture medium in a form of water soluble PCS formulation. The cells were grown for up to 3 days under these conditions, then harvested and washed extensively. The cells (approximately 1- 3 x 106/ per sample) were resuspended in ddH 2 0 and were broken by an osmotic shock after 5 a freezing and thawing cycle. CoQ10 was extracted by a propanol/hexane solvent mixture and its content was measured by the HPLC described above. In order to obtain the mitochondrial fraction, the cells were homogenized in a buffer containing 250mM sucrose, 50mM Tris-HCI pH 7.4, 5 mM MgCl 2 and 10 1 mM EDTA. The homogenates were centrifuged at 800g for 10 min at 4 0 C. The supernatants were collected and were further centrifuged at 10,000g for 10 min at 4*C. The pellets, representing crude mitochondrial fractions, were resuspended in 100 ml of ddH 2 0, extracted with a propanol/hexane solvent mixture and processed for CoQ10 analysis. .15 TablelO. Intracellular uptake of CoQ 1 o by cultured human keratinocytes. CoQ 1 O added Total cellular CoQ 10 content mg/mi of media ng/10 6 cells 0 - control 10 10 21.1 100 49.6 20 38 The data summarized in Table 10 show the intracellular uptake of CoQ10 by human keratinocytes from the aqueous environment of tissue culture media. During the 3-day experimental period the intracellular content of CoQ1O 5 increased approximately 2-fold and 5-fold from the media containing 10 mg/ml and 100 mg/ml of CoQ10 resuspended in the PCS formulation, respectively. Table 11. Increased mitochondrial CoQ 10 content In keratlnocytes. CoQ 1 O added Total cellular CoQ1o content Total mitochondrial mg/mi of ng/10 6 cells content media ng/10 6 cells 0 11 1 10 69 9.8 10 The results shown in Table 11 demonstrate a significant increase of CoQ1O content in the mitochondrial fraction of cells grown for 3 days in the presence of 10 mg/ml of CoQ10. It is expected that, in addition to its function as lipid-soluble antioxidant, the elevated CoQ1O content, particularly in the 15 mitochondria, will potentiate the efficiency of the energy producing respiratory chain which is pivotal for the cellular viability. Example 17 serves to demonstrate the ability of CoQ1O to increase the efficiency of mitochondrial respiratory chain to produce more ATP. 20 39 Example 17. Effects of Coenzyme Qa on cellular ATP content in human NT2 cells. 5 Human teratocarcinoma NT2 (Stratagene, San Diego, CA) were grown in DME medium (GiBco BRL) supplemented with 10 % FBS (fetal bovive serum) and 10mg/ml of CoQ10 which was added directly to the tissue culture medium in a form of water soluble PTS formulation. The cells were harvested at 24 hour intervals , resuspended in a buffer consisting of 0.02M glycine, 0.05M MgSO 4 , 10 0.004M EDTA, pH7.4 and aliquoted into 100pL samples. The ATP content was measured using a luciferin-luciferase bioluminescence assay (Sigma, St. Louis MO). Luciferase catalyses the decarboxylation of luciferin and the hydrolysis of ATP to give pyrophosphate 15 and oxyluciferin. These reactions result in emission of light at 560nm. The intensity of the emitted light is proportional to the ATP concentration. The ATP assay was carried out by mixing 100pL of sample with 75pL of a 0.Smg/mL solution of luciferase-luciferin. Emitted light was detected using a Beckman LS 3801 scintillation counter. A standard curve was prepared ranging from 10 to 20 100 pmols of ATP. ATP levels were expressed as pmols ATP/pg protein. Fig. 3 shows the effect of PTS-CoQ10 composition on cellular ATP level in NY2 cells. The ATP level was reproducibly higher in cells that were cultured for 3 days in the presence of water soluble PTS-CoQ1 0 formulation. The data 25 points represent mean values from three separate experiments +/- SEM. Example 18 shows protective effects of CoQ1O against hypoxia in human neuroblastoma NT2 cells. 30 40 Example 18. Protection against hypoxia. Human teratocarcinoma NT2 (Stratagene, San Diego, CA) were seeded into 25cm2 tissue culture flasks (at a density of 0.3 X 106 cells/ml) and were 5 grown for 3 days in DME medium (Gibco BRL) supplemented with 10 % FBS and in the presence or absence of either 10mg/ml of CoQIO-PTS formulation added directly to the tissue culture media. The flasks were sealed in an anaerobic chamber containing Gas Pak Plus gas generator envelopes and were incubated in the anaerobic conditions at 37 0 C for 17.5 hours in glucose-free 10 medium. Following the hypoxic treatment the cells were placed again in the complete medium (with and without CoQ10 or vitamin E) and were analysed either immediately (time 0) or were cultured for the additional 24 hr under the normoxic conditions. Cell viability was measured by trypan blue exclusion assay. The results are shown in Fig. 4. 15 The protective effects of CoQ1O against hypoxia in NT2 cells is clearly evident. Approximately 50% less cells pre-treated for 3 days with PTs-CoO1O died during the 24 hr recovery period from hypoxia as compared to the cells which did not receive CoQ10. 20 Example 19 shows that CoQ1O is equally effective in protecting cells against cell death triggered by hypoxia as vitamin E. 25 41 Example 19. Comparison of Coenzyme Q10 and vitamin E anti-oxidant function. Human teratocarcinoma NT2 (Stratagene, San Diego, CA) were seeded 5 into 25cm2 tissue culture flasks (at a density of 0.3 X 106 cells/ml) and were grown for 3 days in DME medium (Gibco BRL) supplemented with 10 % FBS and in the presence or absence of either 10mg/ml of CoQ1 0-PTS formulation or the same concentration of vitamin E-PTS formulation, which were added directly to the tissue culture media. The flasks were sealed in an anaerobic chamber 10 containing Gas Pak Plus gas generator envelopes and were incubated in the anaerobic conditions at 370C for 17.5 hours in glucose-free medium. Following the hypoxic treatment the cells were placed again in the complete medium (with and without CoQ1 0 or vitamin E) and were analysed either immediately (time 0) or were cultured for the additional 24 hr under the normoxic conditions. Cell 15 viability was measured by trypan blue exclusion 6ssay. The results are summarized in Fig. 5. In both experimental paradigms, the CoQ10 and Vitamin E treatments, the percentage of death during the 24 hr recovery period from hypoxia is 20 reduced by half. This demonstrates that the protective effects of CoQ1 0 against hypoxia-induced cellular damage are comparable to those of vitamin E, the antioxidant with proven efficacy. Example 20 demonstrates the protective effects of CoQ1O against 25 ischemia/reperfusion caused tissue damage. Although the animal model used is the experimental paradigm of human stroke, the data is relevant for any application where a tissue is damaged as a result of ischemia/reperfusion. 30 42 Example 20. Protective effects of CoQ1O against Ischemla/reperfusion. Adult spontaneously hypertensive rats (SHR) weighting 225-250g , which readily develop stroke characteristic lesions after short periods of vessel 5 occlusion, were used for the middle cerebral artery occlusion model (MCAO). The animals.were anaesthetized and the right common carotid artery was permanently occluded. The skull was exposed and the right middle cerebral artery (MCA) was accessed through a 2 mm burr hole in the skull. Under a dissecting microscope a microclip was applied to the MCA vessel. After a 60 10 min occlusion period, the clip was removed and the'wounds were closed. The body temperature was maintained throughout surgery and recovery at 37.5 0C using a rectal thermistor probe connected to a heating lamp. CoQlO (6 mg/kg) was administered intravenously (neck vein) immediately after the removal of the clip. The effects of 60 min ischemia were quantitated by tetrazolium salt TTC 15 (2,3,5-triphenyl,2H-tetrazolium chloride) In order to quantitate the tissue damage, the brains were cut into 5mm coronal sections and were stained overnight with 2 % TTC. The coloured formazan was extracted using acetonitrile and its concentration was measured 20 spectrophotometrically at 480 nm. The results as expressed as OD/g of dry brain tissue. 43 Table 12. Protective effects of CoQIO against ischemla-induced brain damage Untreated animals CoQio-treated animals Time Left brain Right brain Time after Left. brain Right brain after hemisphere hemisphere reperfusion hemisphere hemisphere reperfu sion Sham 1250.0+/- 1239.0+/- sham 1250.0+/- 1239.0+1 31.8 11.9 31.8 11.9 I day 1208.0+/- 1018.0+/- 1 day 1206.0+/- 1200.0+/ 19.2 26.0 50.2 19.2 2 days 1104.0+/- 898.3+1-19.6 2 days 1084.9+/- 1060.9+/ 36.2 22.2 21.2 Tetrazolium salts are histochemical indicators of mitochondrial respiratory enzymes and are used to detect tissue infarcts. TTC reacts with intact oxidative enzyme systems, such as succinate and NADH dehydrogenase, accepts 10 electrons and becomes reduced to a colored formazan which stains tissue red. By contrast, irreversible damaged mitochondria that do not have intact oxidative system cannot reduce TTC and the tissue remains white unstained. Accordingly, the healthier the tissue the higher the OD readings. Compare values obtained for brains of sham operated control rats ( approximately 1250 44 OD/ g of tissue) and for brains of experimental rats 898.3 OD/g tissue). The protective effects of CoQ1 0 against ischemia-induced tissue damage are clearly evident, higher TTC content and, hence, the higher OD readings were obtained from brains of animals which received CoQ10-treatment postischemically 5 Example 21 illustrate applicability and suitability of water soluble CoQ10 compositions in cosmetics. 45 Example 21. Water soluble CoQ10 compositions in cosmetics. Table 13. Preparation of cosmetics. CoQIO-PCS-600 Classic Moisturizing Cream Final CoQ10 100 mg/ml Oil of Olay concentration 1.5 ml 60 ml 0.25% 3.0 ml 60 ml 0.50% CoQ10-PTS-600 Classic Moisturizing Cream Final CoQ10 100 mg/ml Oil of Olay concentration 1.5 ml 60 ml 0.25% 3.0 ml 60 ml 0.50% CoQ10-PTS-600 Dry Skin Moisturizer Final CoQ10 100 mg/ml Pond's concentration 5 ml 200 ml 0.25% CoQ 1 0-PTS-600 Moisturizing Body Lotion Final CoQ10 100 mg/ml Vaseline concentration 7.5 ml 300 ml 0.25% CoQ1O-PTS-600 Moisturizing Body Lotion Final CoQ10 100 mg/mI Oil of Olay concentration ---- --- ---- -------------------- -- ------------------ 5 ml 200 ml 0.25% 5 46 Table 13 shows amounts of starting materials used to prepare CoQ10 containing skin products which were combined according to the following procedure. The two components were mixed together at room temperature until they formed a uniform composition of a cream in which Coenzyme Q10 5 remained water soluble. This was tested by adding water to a 0.2 ml sample of cream (total volume of I ml). The samples were vigorously vortexed and centrifuged to separate phases. The aqueous phase remained yellow since it contained dissolved CoQ10. The creams were stable and no phase separation was observed even after several months at room temperature. 10 These cosmetics were tested on 20 healthy volunteers over one year period. All reported improved skin conditions, i.e. improved skin elasticity and reduction of wrinkles. None reported an adverse reaction. 15 Example 22 illustrates preparation of water soluble compositions containing polyene macrolide antibiotics. 47 Example 22. Preparation of compositions of anti-fungal antibiotics. Table 14. Preparation of water-soluble formulations of anti-fungal antibiotics. Candicidin 0.01 g PCS-600 or PTS-600 0.02 g
THF/H
2 0 (8:2, v/v) 0.1 ml
H
2 0 2.5 ml Nystatin 0.01 g PCS-600 or PTS-600 0.02 g Glacial acetic acid 0.1 ml
H
2 0 2.5 ml Amphotericin B 0.01 g PCS-600 or PTS-600 0.02 g Methanol/Glacial acetic acid (2:1, v/v) 0.3 ml
H
2 0 2.5 ml Table 14 shows amounts of starting materials used to prepare water soluble compositions of antibiotics. Antibiotics and solubilizing agents were dissolved separately in an appropriate solvent or solvent mixture, The solutions 10 were combined and diluted with water. Solvents and excess of water were removed by evaporation under a reduced pressure. When glacial acetic acid was used as solvent, the co-evaporation with water was repeated several times. Compositions containing 20 mg/ml of antibiotic were obtained by solvent evaporation. They were stable and could be stored frozen for extensive periods 15 of time (8 months). These compositions could be also isolated, further concentrated and sterilized by the technique described in Example 11. The final 48 products were waxy, clear pellets which could be best stored frozen, in vials sealed under argon (up to 8 months). They could be reconstituted in aqueous media (water or saline) to desired concentrations. 5 Example 23 illustrates the preparation of water-soluble compositions containing polyene macrolide antibiotics. Example 23. Preparation of water-soluble formulations of anti-fungal antibiotics 10 Table 15. Preparation of water-soluble formulations of anti-fungal antibiotics Amphotericin B, Nystatin 45 mg PCS-600, PTS-600 or PSS-600 135 - 180 Methanol/Glacial Acetic Acid (3:1 v/v) mg
H
2 0 6.0 ml 4.0 ml Table 15 shows the amounts of starting materials used forthe preparation of water-soluble compositions of antibiotics. The antibiotics and solubilizing 15 agents (1 : 2 to 1: 4 w/w ratio) were dissolved directly in the solvent mixture(methanol/glacial acetic acid 3:1 v/v). The solvents were removed by evaporation under reduced pressure to obtain waxy residues. The residues were then dissolved in water, sterilized in boiling water bath for 5 min and were lyophilized to dryness. The final products were dry powders, which have been 20 stored sealed under argon (for at least 1 year). They were reconstituted in water, saline or dextrose solution to a desired concentration. Typically, solutions containing 5 -30 mg/ml of antibiotics were obtained by this method. The aqueous solutions of Amphotericlcn B were stable for at least 6 months at 40 C. Examples 24 and 25 illustrate diminished toxicity of amphotericin B and 49 Nystatin formulated according to the present invention. Example 24. In vitro haemolysis of red blood cells(RBC) The haemolysis assay was performed using red blood cells (RBC) s isolated from Balb/c mice. The blood was drawn in the presence of heparin (50 units/ml), RBC were isolated and washed three times with phosphate-buffered saline (PBS). For the assay, 0.8 ml of 0.1% RBC (v/v) in PBS were mixed with 0.2 ml of PBS buffer containing increasing concentrations of amphotericin B (final concentrations from 0 to 200 pg/ml), formulated with PSS, PCS and PTS or 10 in the generic Fungizone. The mixtures were incubated at 37 0C for I h with gentle rotation. The samples were spun at 1000xg for.2 min. The content of haemoglobin in the supernatant was measured by absorbance at 541 nm. The amount of haemoglobin, released in the presence of 0.3% Triton X-100 during the same I h at 37 0 C incubation period, was taken as a measure of 100% 15 haemolysis. Table 16. Comparison of haemolytic activity of amphotericin B formulated with PSS, PCS and PTS with the generic Fungizone. Amphotericin B Percentage of Lysed Cells (g/ml) (mean value ± SEM)* PSS - Amph B PCS - Amph B PTS - Amph B Fungizo 3:1 w/w 3:1 w/w 4:1 w/w ne 10 1.0 ±0.3 1.0± 0.5 3.0± 0.6 100.0 25 1.0 ±0.1 1.0± 0.4 7.0 ± 3.0 100.0 50 3.0 ±0.4 7.0 ± 2.0 17.0 ± 8.0 100.0 100 3.0 ± 0.6 14.0 ± 3.0 26.0 ± 6.0 100.0 200 1.7 ± 0.2 22.0 ±2.0 31.5 ± 7.0 100.0 50 Note: * mean value ± standard error of the mean of three separate experiments, each performed in duplicate According to the results presented In Table 16 all three formulations of 5 amphotericin B, prepared according to the present invention, were far less toxic than the generic Fungizone. However, 10 lg/ml of amphotericin B in Fungizone caused 100% RBCs lysis during 1 hr incubation period, 200 jig/ml of the antibiotic formulated with PSS lysed only 1.7% of the cells during the same time. Example 25 In vitro haemolysis of red blood cells(RBC) 10 Table 17. Haemolytic activity of Nystatin formulated with PSS, PCS and PTS. Nystatin Percentage of lysed Cells (ptg/ml) (mean value ± SEM)* PSS - Nystatin PCS - Nystatin PTS - Nystatin Triton X-1 00 formulated at a ratio formulated at a formulated at a 2 :1 w/w ratio 2: 1 w/w ratio 4 : 1 w/w 10 2.5 ± 0.8 2.8 ± 0.5 2.0 ± 0.3 100.0 25 2.3 ± 0.7 2.5 ± 0.6 2.0 ±0.4 100.0 100 2.2 ±0.6 2.1 ± 0.7 2.3 ± 0.5 100.0 200 2.1 ± 0.7 2.3 ± 0.7 2.4 ± 0.5 100.0 Note: * mean value ± standard error of the mean of four separate samples. As shown in Table 17 all three formulations of nystatin, prepared according to the present invention, were non-toxic within the concentration range of 10 to 200 15 ig/ml. 51 Example 26 illustrates in vivo efficacy of the antibiotic formulations. Example 26. Reduction of C. neoformans burden in mouse brain following 7-day treatment with amphotericin B formulated either with PCS or PTS 5 according to the present invention or with the generic Fungizone. In vivo efficacy testing of amphotericin B formulations against systemic infection of murine Cryptococcus neoformans was performed on 8 weeks old female CD1 mice according to the following protocol. All animals were 10 intravenously inoculated with 1.84 x 103 colony forming units (CFU) of C. neoformans. Four days later the mice were subjected to a 7-day treatment regimen with either the generic Fungizone or amphotericin B -PCS, amphotericin B -PTS and PCS alone (vehicle). The antibiotic formulations were diluted with 5% dextrose to a final concentration of 250 Ag/ml and the mice 15 received, intravenously, 0.2 ml/dose (equivalent to 2 mg/kg body weight) of the appropriate antifungal formulation. 24 hr after the last antifungal treatment, mice were killed and brains were harvested, homogenized and plated on SabDex agar. C. neoformans colonies were counted after a 3 day incubation at 26 *C. 20 The infection burden of animals treated with the antimycotic agents was compared to the vehicle treatment. 52 Table 18. C. neoformans infection burden in mice brain after 7-day treatment with amphotericin B - PCS, amphotericin B - PTS and Fungizone Antimycotic Number Burden of C. neoformans Infection Statistical formulation of mice (mean Log 1 oof CFU ±SEM) reduction analysis (n) (percentage) (p value) Fungizone 7 5.18 ± 0.58 99.0 < 0.0001 Amph B-PCS 10 5.37 ± 0.58 98.5 < 0.0001 Amph B-PTS 10 5.51 ± 0.41 98.0 0.0003 Vehicle 8 7.18 ± 0.30 0 (PCS alone) The data presented in Table 18 show that both amphotericin B formulations, prepared according to the present invention, significantly reduced the C. 5 neoformans burden in brains and that they were equally effective as the generic Fungizone. Example 27 illustrates a release of free a-tocopherol into bloodstream following either oral or intravenous administration of PTS. 10 Example 27. Systemic release of vitamin E following administration of PTS PTS, dissolved In water (50 mg/ml), was administered to Sprague Dawley 15 male rats (300-350 g) either orally or intravenously at a dose of 50 mg/kg body weight. Heparinized blood samples were collected at 0, 3, 8 and 24 hr following 53 PTS administration. Blood plasma samples were obtained and analyzed for the content of alpha-tocopherol using an HPLC method using a Supercosil LC-1 8 DB column and a mobile phase of ethanol:methanol (80:20 v/v) at a flow rate of .1ml/min. Beckman System Karat software was used for data quantification. 5 Table 19. Concentration of a-tocopherol In rat blood plasma following administration of PTS Time Oral administration Intravenous administration (hours) (pg/ml) (pg/ml) 0 (control) 6.13 ±1.18 (n= 3) 6.13 ± 1.18 (n=3) 3 8.65 ± 1.40 (n=3) 18.48 ± 2.40 (n=3) 8 9.33 ± 2.10 (n=3) 11.19 ± 3.11 (n=3) 24 8.31 ± 0.60 (n=3) 10.59 ± 1.48 (n=3) Elevated plasma content of a-tocopherol indicates a systemic conversion by the animal body, of PTS to active non-toxic vitamin E. 10 Example 28 illustrates the ability to dissolve in water different oils with a high content of polyunsaturated fatty acids (PUFA) such as linoleic, linolenic, arachidonic eicosapentaenoic (EPA), docosahexaenoic (DHA) and their derivatives. 15 Example 28. Preparation of water-soluble formulations of oils containing PUFA Oils were mixed directly with either PTS-600 or PSS-600 at a ratio 1:2 to 1:3 w/w. The mixture was then heated to a temperature of 40-50 0 C to form a 54 water-soluble composition in the form of a clear melt. The mixture was then diluted with water to form a solution. These water solutions of PUFA were stable for several months, when refrigerated. Table 20. Preparation of water-soluble formulation of PUFA Flaxseed oil, fish oil .1.0 g PTS-600, PSS-600 2.0 - 3.0 g 5 Example 29 illustrates the ability to dissolve in water terpenes and terpenoids including: squalene, geraniol, famesol, p-carotene, astaxanthin, canthaxanthin, zeaxanthin, cryptoxanthin, lutein and lycopene. Such compounds are useful as antioxidants, colorants and fragrances. 10 Example 29 Solubilization of terpenes and terpenolds Table 21. Preparation of water-soluble formulation of squalene Squalene 1.0 g PTS-600, PCS-600, PSS-600 3.0 g 15 The components are mixed directly with either PTS-600, PCS-600 or PSS-600, at a ratio 1:3 w/w. The mixture was then heated to a temperature of 40-50 0C to form a water-soluble composition in the form of a clear melt. The mixture was then diluted with water to form a solution. The solution is stable for several months, when refrigerated. 20 55 Table 22. Preparation of water-soluble of astaxanthin Astaxanthin 0.005 g PTS-600 0.020 g THF 0.5 ml
H
2 0 5.0 ml Astaxanthin and PTS-600, in a weight ratio of 1:4, are dissolved in a water miscible solvent (THF) and the mixture is diluted with water to form an aqueous 5 solution. The solution was then concentrated under a reduced pressure to remove the organic solvent and excess of water. The concentrated solution (2 mg/ml) was refrigerated and remained stable for several months. Example 30 illustrates water solubilization of a-tocopheryl acetate. 56 Table 23. Preparation of water-soluble a-tocopheryl acetate a- tocopheryl acetate 0.10 g PTS-600 0.51 g THF 1.0 ml
H
2 0 20.0 ml a- tocopheryl acetate 0.10 g PTS-400 0.43 g THF 2.0 ml
H
2 0 20.0 ml a- tocopheryl acetate 0.10 g PTS-400 0.43 g a- tocopheryl acetate 0.10 g PTS-600 0.51 g a-tocopheryl acetate 0.10 g PTrienS-600 0.51 g (polyoxyethany.-tocotrienyl sebacate) Table 23 shows amounts of starting materials used for various water soluble formulations of x- tocopheryl acetate. The ratio of solubilizing agent to 5 a- tocopheryl acetate was 2 :1 mol/mol or 4.5 : 1 w/w for PTS-400 and 5.5: 1 w/w for PTS-600. Water-soluble formulations were obtained either with the aid of an auxiliary solvent or by the direct admixing method. The direct admixing was done at an elevated temperature of hot water bath (80-1000 C). The mixture could be diluted with water to a desired concentration of a- tocopheryl acetate. 57 The aqueous solutions obtained by the direct admixing were slightly more opaque than the solutions obtained with the aid of auxiliary solvent. The solutions were stable when refrigerated. 5 Example 31 illustrates a method for the preparation polyoxyethanyl tocotrienyl sebacate (PTrienS). Example 31. Synthesis of polyoxyethanyl tocotrienyl sebacate (PTrienS 600). 10 2.15 g of tocotrienols (NuTriene@, Eastmnan Chemical Company) and 0.925 ml of triethylamine (TEA) dissolved in 5 ml dry ethyl acetate were added dropwise to 1.45 ml of sebacoyl chloride, while stirring and under anhydrous conditions. The reaction was carried out for 5 min at room temperature, at which time 3 g of PEG-600 (polyethylene glycol, Sigma Chem. Co., product # P-3390) 15 and 1.85 ml of TEA, dissolved in 5 ml of dry ethyl acetate, were added dropwise while cooling in an ice bath. The reaction was continued with constant stirring for an additional 5 min at room temperature. The reaction mixture was extracted four times with 5 ml (each time) of a saturated solution of NaCl. The reaction product remained soluble in the organic phase from which ethyl acetate was 20 removed under reduced pressure, leaving a waxy residue of the product. The product was further dissolved in 50 ml of methanol and the methanol-insoluble by-products were removed by centrifugation, and methanol was evaporated under reduced pressure. The solid waxy product was dissolved in 20 ml of water and lyophilized, yielding approximately 1.3 g of brownish -waxy solid of PTrienS 25 600. Example 32 illustrates water solubilization of tocotrienols. Example 32 water solubilization of tocotrienols 30 58 Table 24. Preparation of water-soluble tocotrienols NuTriene 0.1 g PTS-600 0.56 g THF 1.0 ml
H
2 0 30 ml NuTriene 0.1 g PTS-600 0.56 g NuTriene 0.1 g PTrienS-600 0.56 g Table 24 shows amounts of starting materials used for various water soluble formulations of tocotrienols. The ratio of solubilizing agent to tocotrienols was about 2 :1 mol/mol or 5.5: 1 w/w. Water-soluble formulations 5 were obtained either with the aid of an auxiliary solvent or by the direct admixing method. The direct admixing was done at elevated temperature of hot water bath (80-100* C). The mixture was diluted with water to a desired concentration of tocotrienols. The aqueous solutions obtained with PTS were opaque, whereras the solution obtained with PTrienS was clear. The solutions were 10 stable when refrigerated. Example 33 illustrates water solubilization of Coenzyme Q 10 in PTrienS 600 and PTS-400. 15 Example 33. Preparation of water-soluble formulations of Coenzyme Q 1 0 Table 25. Preparation of water-soluble Coenzyme Q 10 Coenzyme Q 10 0.012 g PTS-400 0.028 g Coenzyme Q 10 0.010 g PTrienS-600 0.035 g 59 Table25 shows amounts of starting materials used to prepare water soluble formulations of Coenzyme Q 10 . The ratio of Coenzyme Q10 to PTS-400 was 1: 2.5 w/w and to PtrienS-600 1:3.5 w/w. The formulations were obtained by a 5 direct admixing at elevated temperature of hot water bath (80 -100* C). The mixture was diluted with water to a desired concentration of Coenzyme Q10 . The aqueous solutions were stable when refrigerated. It is to be understood that, if any prior art publication is referred to 10 herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. In the claims which follow and in the preceding description of the 15 invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. 20 60 738305_1 (GHMatters) P50274AU.
Claims (11)
1. A water-soluble composition, comprising (a) a solubilizing agent selected from the group consisting of s (i) polyoxyethanyl-sitosterol sebacate (PSS) and (ii) polyoxyethanyl-a-tocopheryl sebacate (PTS), and (b) a compound having a high content of polyunsaturated fatty acids.
2. The composition of claim 1, wherein the compound is an oil with a high content of polyunsaturated fatty acids. 10
3. The composition of claim 1 or 2, wherein the polyunsaturated fatty acids comprise linoleic, linolenic, arachidonic, eicosapentaenoic, or docosahexaenoic fatty acids.
4. The composition of any one of claims 1-3, wherein the compound is an oil, and wherein the solubilizing agent and oil are formulated in a weight 15 ratio of solubilizing agent to oil of 2:1 to 3:1.
5. The composition of any one of claims 1-3, wherein the molar ratio of solubilising agent to the compound having a high content of polyunsaturated fatty acid is 1:1 to 5.5:1.
6. The composition of claim 5, wherein the molar ratio is about 2:1. 20
7. The composition of any one of claims 2-4, wherein the oil is selected from the group consisting of flaxseed oil and fish oil.
8. The composition of any preceding claim, wherein the compound is a fish oil.
9. The composition of any preceding claim, wherein the solubilizing 25 agent is polyoxyethanyl-a-tocopheryl sebacate.
10. The composition of any preceding claim, wherein the solubilising agent is polyoxyethanyl-a-tocopheryl sebacate and the compound is a fish oil.
11. A water soluble composition, substantially as herein described with reference to the Examples and/or Figures. 61 2476074_1 (GHMatters) P50274.AU.1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011201888A AU2011201888A1 (en) | 2001-02-02 | 2011-04-27 | Water-soluble compositions of bioactive lipophilic compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/773,592 | 2001-02-02 | ||
AU2002231502A AU2002231502A1 (en) | 2001-02-02 | 2002-01-31 | Water-soluble compositions of bioactive lipophilic compounds |
AU2007231911A AU2007231911A1 (en) | 2001-02-02 | 2007-11-12 | Water-soluble compositions of bioactive lipophilic compounds |
AU2011201888A AU2011201888A1 (en) | 2001-02-02 | 2011-04-27 | Water-soluble compositions of bioactive lipophilic compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007231911A Division AU2007231911A1 (en) | 2001-02-02 | 2007-11-12 | Water-soluble compositions of bioactive lipophilic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2011201888A1 true AU2011201888A1 (en) | 2011-05-19 |
Family
ID=44012678
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007231911A Abandoned AU2007231911A1 (en) | 2001-02-02 | 2007-11-12 | Water-soluble compositions of bioactive lipophilic compounds |
AU2011201888A Ceased AU2011201888A1 (en) | 2001-02-02 | 2011-04-27 | Water-soluble compositions of bioactive lipophilic compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007231911A Abandoned AU2007231911A1 (en) | 2001-02-02 | 2007-11-12 | Water-soluble compositions of bioactive lipophilic compounds |
Country Status (1)
Country | Link |
---|---|
AU (2) | AU2007231911A1 (en) |
-
2007
- 2007-11-12 AU AU2007231911A patent/AU2007231911A1/en not_active Abandoned
-
2011
- 2011-04-27 AU AU2011201888A patent/AU2011201888A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2007231911A8 (en) | 2007-11-29 |
AU2007231911A1 (en) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6632443B2 (en) | Water-soluble compositions of bioactive lipophilic compounds | |
US8524696B2 (en) | Water-soluble compositions of bioactive lipophilic compounds | |
CA2369300C (en) | Water-soluble compositions of bioactive lipophilic compounds | |
US5972993A (en) | Composition and method for treating rosacea and sensitive skin with free radical scavengers | |
EP2727580B1 (en) | Astaxanthin-containing composition, method for manufacturing same, and cosmetic | |
US7648710B2 (en) | Formulation containing phosphate derivatives of electron transfer agents | |
EP1339412B1 (en) | Formulation containing phosphate derivatives of electron transfer agents | |
Borowy-Borowski et al. | Unique technology for solubilization and delivery of highly lipophilic bioactive molecules | |
JP2005132822A (en) | Stabilized composition containing oxygen unstable active agent | |
AU2011201888A1 (en) | Water-soluble compositions of bioactive lipophilic compounds | |
KR950013763B1 (en) | Pharmaceutical compositions containing retinoic glucuronide | |
AU2002231502A1 (en) | Water-soluble compositions of bioactive lipophilic compounds | |
JP2006206537A (en) | External preparation for skin and method for bleaching skin | |
KR20150011763A (en) | Chlorin e6 for the treatment, prevention or improvement of acne | |
JP2002097147A (en) | Microbial lipase inhibitor, skin care preparation against pimple and skin care preparation against dandruff containing the same | |
JPH09263541A (en) | Cosmetic composition and medicinal composition containing aqueous extract of selaginella moellendorfii hieron | |
AU2002214820A1 (en) | Formulation containing phosphate derivatives of electron transfer agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK16 | Application refused |